help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kol, S.
Right arrow Articles by Adashi, E. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kol, S.
Right arrow Articles by Adashi, E. Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
*NITRIC OXIDE
Endocrinology Vol. 138, No. 1 322-331
Copyright © 1997 by The Endocrine Society

ARTICLES

The Rat Ovarian Phospholipase A2 System: Gene Expression, Cellular Localization, Activity Characterization, and Interleukin-1 Dependence1

Shahar Kol2, Kristiina Ruutiainen-Altman3, Izhar Ben-Shlomo4, Donna W. Payne, Motomu Ando and Eli Y. Adashi

Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland 21201

Address all correspondence and requests for reprints to: Dr. Eli Y. Adashi, Departments of Obstetrics, Gynecology, and Physiology, University of Maryland School of Medicine, 11–013 BRB, 655 West Baltimore Street, Baltimore, Maryland 21201. E-mail: eadashi{at}umabnet.ab.umd.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have previously demonstrated that interleukin-1ß (IL-1ß), a putative intermediary in the ovulatory process, is a potent stimulator of ovarian PG biosynthesis. In this communication, we examine the possibility that this IL-1 effect reflects in part the induction of arachidonic acid mobilization by phospholipase A2 (PLA2). Molecular probing of whole ovarian material revealed the immature rat ovary to be a site of modest secretory PLA2 (sPLA2) gene expression. However, no change in ovarian sPLA2 gene expression was noted during the periovulatory period. Comparable probing for cytosolic PLA2 (cPLA2) failed to disclose a quantifiable signal. However, in situ hybridization localized both sPLA2 and cPLA2 (sPLA2 > cPLA2) transcripts to the granulosa cell layer of the ovarian follicle. Treatment of cultured whole ovarian dispersates with IL-1ß produced significant (P < 0.01) increments in the steady state levels of transcripts corresponding to both sPLA2 (1.7-fold increase) and cPLA2 (5-fold increase), an effect reversed by an IL-1 receptor antagonist, suggesting mediation via a specific IL-1 receptor. Treatment with cycloheximide, a protein synthesis inhibitor, resulted in significant attenuation of the ability of IL-1ß to up-regulate sPLA2 and cPLA2 gene expression as well as medium PLA2 activity. Treatment with aminoguanidine, an inhibitor of inducible nitric oxide synthase, led to augmentation of the ability of IL-1ß to up-regulate sPLA2 and cPLA2 gene expression as well as medium PLA2 activity. Total cellular PLA2 activity proved time, cell density, and calcium dependent, with an optimal pH of 8.0–9.0 and Km values in the low micromolar range (2–5 µM). Our observations 1) establish the rat ovary as a site of sPLA2 and cPLA2 gene expression, 2) localize the corresponding transcripts to the granulosa cell layer, and 3) establish IL-1ß as an up-regulatory agent for ovarian sPLA2 and cPLA2 gene expression as well as for ovarian PLA2 activity. These findings also indicate that the IL-1 effect is 1) receptor mediated, 2) contingent in part upon de novo protein biosynthesis, and 3) inhibited by nitric oxide. These observations support the proposition that PLA2 may be a key component in the IL-1-stimulated biosynthesis of ovarian PGs.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
PHOSPHOLIPASE A2 (PLA2) is the enzyme that catalyses the hydrolysis of fatty acids esterified at the sn-2 position of phospholipids. Arachidonic acid (AA), a precursor in the eicosanoid biosynthetic cascade, is predominantly found at this position. Thus, cleavage of the AA residue will, after additional processing, give rise to potent proinflammatory mediators (i.e. PGs and leukotrienes). Consequently, it is the PLA2-mediated release of arachidonic acid that constitutes the rate-limiting event in eicosanoid production (1).

Evidence to date (reviewed in Refs. 2–4) suggests that mammalian PLA2 is a heterogeneous family of enzymes that includes two classes of proteins: secretory, low mol wt (14 kDa; sPLA2) and cytosolic, high mol wt (85–110 kDa; cPLA2). The former is further subclassified into a digestive group I (synthesized and secreted mainly by the pancreas) and a nondigestive group II (synthesized and secreted by many cell types). PLA2 isoenzymes are not only concerned with the hydrolysis of phospholipids, but may also play important roles in cellular growth and differentiation (1), acting via an ever-growing number of specific cell surface receptors (5, 6).

The relevance of PLA2 to ovarian physiology is suggested by the importance of PG biosynthesis to the ovulatory cascade (7). Moreover, ovarian PG biosynthesis is stimulated by interleukin-1ß (IL-1ß) (8, 9, 10), a putative player in the ovulation process (11, 12, 13, 14, 15). We, therefore, set out to characterize rat ovarian PLA2 activity, sPLA2 and cPLA2 gene expression, cellular localization, and IL-1ß dependence.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
Immature Sprague-Dawley female rats from Zivic-Miller Laboratories (Zelienople, PA) were killed by CO2 asphyxiation on day 25 of life. The project was approved by the institutional animal care and use committee.

Reagents and hormones
Phosphatidylcholine L-{alpha}-1-stearoyl-2-arachidonyl (arachidonyl-5,6,8,9,11,12,14,15-N-3H; PCSA; 88 Ci/mmol), phosphatidylcholine L-{alpha}-dipalmitoyl (2-palmitoyl-9,10-N-3H; PCDP; 42 Ci/mmol], palmitic acid (9,10-N-3H; PA; 39 Ci/mmol), PGF2{alpha} (5,6,8,9,11,12,14,15-N-3H; 200 Ci/mmol), PGE2 (5,6,8,9,11,12,14,15-N-3H; 154 Ci/mmol], AA (5,6,8,9,11,12,14,15-N-3H; 100 Ci/mmol), and [{alpha}-32P]UTP (800 Ci/mmol) were purchased from DuPont-New England Nuclear (Boston, MA). The corresponding unlabeled materials, ribonuclease A (RNase A), PMSG, aminoguanidine hemisulfate salt (AG), cycloheximide (CHX), and other chemicals (unless specified otherwise) were purchased from Sigma Chemical Co. (St. Louis, MO). McCoy’s 5a (serum-free) medium, penicillin-streptomycin solution, BSA, deoxyribonuclease, and trypan blue stain were obtained from Life Technologies (Grand Island, NY). Collagenase (Clostridium histolyticum; CLS type I; 144 U/mg) was purchased from Worthington Biochemical Corp. (Freehold, NJ). Hexane, methanol, and 2-propanol were obtained from J. T. Baker, Inc. (Phillipsburg NJ). Chloroform was purchased from Fisher Scientific (Fairlawn, NJ).

Recombinant human IL-1ß (2 x 107 U/mg) was generously provided by Drs. Errol B. de Souza and C. E. Newton of DuPont Merck Pharmaceutical Co. (Wilmington, DE). A recombinantly expressed preparation of the naturally occurring human IL-1 receptor antagonist (IL-1RA) was generously provided by Dr. Daniel E. Tracey, Upjohn Co. (Kalamazoo, MI). Highly purified hCG (CR-127, 14,900 IU/mg) was generously provided by Dr. R. E. Canfield through the Center for Population Research, NICHHD, NIH (Bethesda, MD). RNase T1 was obtained from Pharmacia (Piscataway, NJ). AmpliTaq polymerase was purchased from Perkin-Elmer (Norwalk, CT). Alkaline phosphatase-conjugated antidigoxigenin polyclonal antibody Fab fragments, digoxigenin-UTP, nitroblue tetrazolium, and 5-bromo-4-chloro-3-inodyl-phosphate were purchased from Boehringer Mannheim (Indianapolis, IN). Ecl136II was obtained from New England Biolabs (Beverly, MA). T7 RNA polymerase, pGEM7Zf+, and other molecular grade reagents were obtained from Promega (Madison, WI).

Tissue culture procedures
Whole ovarian dispersates were prepared and maintained as previously described (16).

Cell-free PLA2 enzyme assay
Cellular or extracellular PLA2 activity was determined by measuring the release of 3H-labeled fatty acid from the sn-2 position of 3H-labeled PCSA or PCDP substrates (AA or PA, respectively). Whole ovarian dispersates (5 x 105 viable cells/tube) were initially cultured as previously described (16) for 48 h in the absence or presence of the specified treatments. Media were then collected, and the cells were washed once with 100 mM HEPES buffer (pH 8.0) and suspended in 1 ml of the same buffer. Cells were sonicated on ice (twice) for 5 sec (Vibra Cell, Sonics and Materials, Danbury, CT). A sonicate volume representing a specified number of cells or a medium aliquot was then incubated with radiolabeled PCSA or PCDP (5 µM except as noted, dissolved in methanol) for the duration indicated at 37 C in a total assay volume of 1 ml. Except as noted, final parameters in the assay were 100 mM HEPES (pH 8), 5% methanol, and 2 mM CaCl2. The enzymatic reaction was terminated with 7% formic acid (final pH 3.5), and the resultant products were extracted with ethyl acetate and detected by HPLC as follows. Extracts were evaporated to dryness in a Speed-Vac centrifuge (Savant Instruments, Farmingdale, NY), and the residue was resuspended in 250 µl hexane-isopropanol-acetic acid (95:5:0.025). Sample constituents were fractionated using a Waters (Milford, MA) HPLC system on a normal phase diol column (10 mm; LiChrosorb Diol, EM Reagents, Gibbstown, NJ) with a concave gradient of hexane-isopropanol (95:5 to 60:40) at 2 ml/min. The column was calibrated with authentic [3H]AA, [3H]PGE2, [3H]PGF2{alpha}, and [3H]PA. Radiolabeled metabolites of PCSA or PCDP were detected and quantified by on-line scintillation counting with a Radiomatic Flow Detector (Packard Instrument Co., Downers Grove, IL). The ratio of labeled product to labeled substrate was multiplied by the initial substrate concentration (5 µM) to calculate the rate of enzymatic conversion to product (picomoles per 105 cells/h). Values were also corrected for substrate availability and product recovery.

Nucleic acid probes
A plasmid containing a 750-bp SmaI/EcoRI insert of the complementary DNA (cDNA) encoding rat type II sPLA2 (17) was kindly provided by Dr. J. Ishizaki from Shionogi Research Laboratories (Osaka, Japan). For the purpose of RNase protection assays, a BamHI fragment was excised and subcloned into pGEM7Zf+. This latter construct was then linearized with Ecl136II and transcribed with T7 RNA polymerase in the presence of [{alpha}-32P]UTP to yield a 535-nucleotide antisense riboprobe that, upon hybridization, was projected to generate a 452-nucleotide protected fragment.

A full-length cDNA of the rat 85-kDa cPLA2 (18) was kindly provided by Dr. Yuji Owada from Tohoku University (Sendai, Japan) in a transcribable vector (pBluescript II SK+). As the transcribed region contained a polyadenylated tail and several A-rich regions, the cDNA was modified to ensure the generation of a high specific activity riboprobe. Specifically, BamHI was used to remove some of the 3'-end of the cDNA. After self-ligation, the product was linearized with PvuII and transcribed with T7 RNA polymerase to yield a 328-nucleotide antisense riboprobe that, upon hybridization, was projected to generate a 253-nucleotide protected fragment corresponding to the translated region of the cDNA.

The ribosomal protein large 19 (RPL19) probe was generated and employed as previously described (19).

RNA extraction
Total RNA of cultured cells and whole ovarian material was extracted with RNAzol-B (Tel Test, Friendswood, TX) according to the manufacturer’s protocol.

RNase protection assay
Linearized DNA templates were transcribed with T7 RNA polymerase to specific activities of 800 Ci/mmol [{alpha}-32P]UTP (cPLA2 and sPLA2) or 160 Ci/mmol [{alpha}-32P]UTP (RPL19). The riboprobes were gel-purified as previously described (20) in an effort to eliminate transcribed products that were shorter than the full-length probes. The assay was performed as previously described (21).

The hormonally independent RPL19 messenger RNA signal was used to normalize the sPLA2 and cPLA2 messenger RNA data for possible variation in RNA loads. Specifically, the net (respective background subtracted) PLA2 to net RPL19 ratio was calculated for each sample.

In situ hybridization
Sense strand for sPLA2 was created by linearizing the plasmid with HindIII. Transcription with SP6 created a riboprobe of 698 bp. The probe concentration for the sense and antisense sPLA2 was 4 ng/µl. The washes were performed as described previously (19). Additional washes [at room temperature for 10 min in 0.2 x SSC (standard saline citrate) and for 10 min in 0.1 x SSC at 47 C] were necessary to reduce the background. Three in situ hybridizations of three in vivo sets of ovaries were carried out.

The probe concentration for cPLA2 was 8 ng/µl. The sense probe for the type I IL-1 receptor (19), in the same concentration, was used a negative control. The posthybridization washes were performed as described previously (19). Three in situ hybridizations of three in vivo sets of ovaries were carried out. In one set, the cPLA2 signal was weak; in the other two sets, the signal was clear, and the signal to noise ratio was excellent.

For each in situ experiment, use was also made of other unrelated riboprobes as internal controls (glucose transporter 3, PG endoperoxidase synthase-2, IL-1ß, and type I IL-1 receptor), which labeled different pools of follicles. The specificity of the assay was validated with respect to the antisense probes by identifying both signal-positive and signal-negative follicles within the same ovary.

Statistical analysis
Except as noted, each experiment was replicated a minimum of three times. Data points are the mean ± SE, and statistical significance (Fisher’s protected least significance difference) was determined by ANOVA and Student’s t test. Statistical values were calculated using Statview 512+ for MacIntosh (Brain Power, Calabasas, CA).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
sPLA2 and cPLA2 gene expression in vivo during a simulated estrous cycle
To assess sPLA2 and cPLA2 gene expression during a simulated estrous cycle, immature rats were PMSG-primed/hCG-triggered. Rats were killed at the indicated time points, and ovarian transcripts for sPLA2 were detected by a solution hybridization RNase protection assay. As shown (Fig. 1Go), faint protected fragments for sPLA2 were apparent in whole ovarian material throughout the periovulatory period. However, no statistically significant changes were noted relative to time zero. Probing for cPLA2 yielded signals too faint for meaningful quantification (not shown).



View larger version (45K):
[in this window]
[in a new window]
  		Figure 1. sPLA2 and cPLA2 gene expression in PMSG/hCG-primed rats. Intact 25-day-old rats were injected (sc) with PMSG (15 IU/rat). Ovulation was triggered 48 h later with hCG (15 IU/rat). The animals were killed at the indicated time points, and total RNA was extracted and subjected to a solution hybridization/RNase protection assay with 32P-labeled rat antisense riboprobes for sPLA2 and RPL19. The intensity of the signals was quantified as described. The bar graph depicts the mean ± SE of three experiments. Data were normalized to the value obtained for the untreated rats (time zero). In the representative autoradiograph, the full-length riboprobes are marked in italics, and the protected fragments are indicated in boldface.

 
cPLA2 and sPLA2 gene expression in vitro: effect of treatment with IL-1ß
Given the negligible in vivo expression of cPLA2 as detected in whole ovarian material, we probed for cPLA2 transcripts in vitro. Whole ovarian dispersates were cultured for 48 h in the absence or presence of IL-1ß with or without IL-1RA. As shown (Fig. 2Go), treatment with IL-1ß produced a 5-fold increase (P < 0.01) in the relative expression of cPLA2 over that in untreated controls, an effect reversed by IL-1RA. These observations support the views that the rat ovary is a site of cPLA2 expression, that ovarian cPLA2 transcripts are IL-1ß dependent, and that this IL-1ß effect is receptor mediated. The IL-1ß-mediated increase in sPLA2 transcripts is also shown below (Figs. 6Go and 10Go).



View larger version (53K):
[in this window]
[in a new window]
  		Figure 2. cPLA2 gene expression by cultured whole ovarian dispersates from immature rats: effect of treatment with IL-1ß. Whole ovarian dispersates (1.5 x 106 cells/dish) were cultured for 48 h in the absence or presence of IL-1ß (50 ng/ml) with or without IL-1RA (5 µg/ml). The resultant RNA samples were subjected to a RNase protection assay using 32P-labeled rat antisense riboprobes for cPLA2 and RPL19. The left panel depicts the mean ± SE of three experiments. In each individual experiment, data were normalized relative to the peak value. In the representative autoradiograph (right panel), the protected fragments are indicated in boldface.

 


View larger version (25K):
[in this window]
[in a new window]
  		Figure 6. IL-1ß-induced sPLA2 expression by cultured whole ovarian dispersates: protein synthesis dependence. Whole ovarian dispersates were cultured and analyzed as described in Fig. 5Go, except that rat antisense sPLA2 riboprobes were used. Data were normalized relative to untreated controls (top panel). In the representative autoradiograph (bottom panel), the protected fragments for sPLA2 are shown.

 


View larger version (63K):
[in this window]
[in a new window]
  		Figure 10. IL-1ß-induced sPLA2 gene expression: nitric oxide dependence. Whole ovarian dispersates (1.5 x 106 cells/dish) were cultured and analyzed as described in Fig. 9Go, except that rat antisense sPLA2 riboprobe was used.

 
Cellular localization of cPLA2 and sPLA2 transcripts: in situ hybridization studies
To establish the identity of the ovarian cell population responsible for cPLA2 and sPLA2 gene expression, ovaries were obtained from untreated and periovulatory 25-day-old rats and processed for in situ hybridization. As shown (Fig. 3Go), probing with an antisense cPLA2 riboprobe localized the signal to the granulosa cell (black arrow) layer in both periovulatory (Fig. 3AGo) and untreated immature (Fig. 3BGo) ovaries. The signal appeared to intensify toward the antrum. As shown in an enlarged view (Fig. 3CGo), the granulosa cell signal was confined by the basement membrane (black arrow). Probing with an antisense sPLA2 riboprobe yielded a more robust signal, which was similarly localized to the granulosa cell layer in both untreated (Fig. 4AGo) and periovulatory (Fig. 4BGo) immature ovaries. The signal appeared more intense in antral cells. Probing with the corresponding sense riboprobes proved negative (not shown). Thus, PLA2 transcripts (sPLA2 > cPLA2) are granulosa cell exclusive in both the untreated and periovulatory state.



View larger version (134K):
[in this window]
[in a new window]
  		Figure 3. Cellular localization of cPLA2 transcripts. Ovaries were obtained from untreated or PMSG-primed 25-day-old rats and processed for in situ hybridization using a digoxigenin-labeled rat cPLA2 antisense riboprobe. A, x40 magnification of a section from a PMSG/hCG (8 h)-primed ovary. The black arrows denote follicles with positively stained granulosa cells. B, x100 magnification of a section from an untreated ovary. The black arrows denote follicles with positively stained granulosa cells. C, x400 magnification of a section from a PMSG/hCG (8 h)-primed ovary. GC, Granulosa cells (the white arrow denotes the cumulus complex; black arrows denote the basement membrane).

 


View larger version (122K):
[in this window]
[in a new window]
  		Figure 4. Cellular localization of sPLA2 transcripts. Ovaries from 25-day-old rats were processed for in situ hybridization using a digoxigenin-labeled rat sPLA2 antisense riboprobe. A, x4 magnification of a section from an untreated ovary. The black arrows denote follicles with positively stained granulosa cells. B, x400 magnification of a section from a PMSG/hCG (24 h)-primed ovary. The black arrows denote the follicular basement membrane. O, Oocyte; GC, granulosa cells.

 
IL-1ß-induced PLA2 expression and activity by cultured whole ovarian dispersates: dependence on protein synthesis
We examined the role of de novo protein synthesis on basal and IL-1ß-induced transcripts encoding cPLA2 and sPLA2. As shown (Fig. 5Go), treatment with cycloheximide (0.1 µg/ml), an established inhibitor of protein biosynthesis, produced significant (P < 0.001) blockade of IL-1ß-induced (but not basal) cPLA2 gene expression. Significant (P < 0.05) attenuation of both basal and IL-1ß-induced sPLA2 gene expression were also documented (Fig. 6Go). The relative specificity of the cycloheximide effect was suggested by its lack of effect on RPL19 expression (Fig. 5Go). These findings suggest that the induction of PLA2 transcripts (but not basal PLA2 expression) is contingent in part upon de novo protein biosynthesis.



View larger version (46K):
[in this window]
[in a new window]
  		Figure 5. IL-1ß-induced cPLA2 expression by cultured whole ovarian dispersates: protein synthesis dependence. Whole ovarian dispersates (1.5 x 106 cells/dish) were cultured for 48 h in the in the absence or presence of IL-1ß (50 ng/ml) with or without CHX (0.1 µg/ml). The resultant RNA samples were subjected to a RNase protection assay using 32P-labeled rat antisense riboprobes for cPLA2 and RPL19 as described. The left panel depicts the mean ± SE of three experiments. In each experiment, data were normalized to the peak value. In the representative autoradiograph (right panel), the protected fragments are indicated in boldface.

 
Medium PLA2 activity was assessed using a PA-containing substrate (PCDP) that is cleaved only by the sPLA2 isoenzyme (2). A comparable cPLA2-selective substrate does not exist. As shown (Fig. 7Go), medium PLA2 activity was stimulated by IL-1ß, similar to the IL-1ß-mediated stimulation of sPLA2 and cPLA2 transcripts. Concurrent treatment with cycloheximide resulted in substantial inhibition of both basal and IL-1ß-induced medium PLA2 activity (P < 0.01 and P < 0.05, respectively). These observations suggest that the PLA2 activity detected in medium conditioned by ovarian cells is dependent on the de novo synthesis and secretion of a protein.



View larger version (21K):
[in this window]
[in a new window]
  		Figure 7. IL-1ß-induced medium sPLA2 activity in cultured whole ovarian dispersates: protein synthesis dependence. Whole ovarian dispersates (1.5 x 106 cells/dish) were cultured for 48 h in the absence or presence of IL-1ß (50 ng/ml) with or without CHX (0.1 mg/ml). At the conclusion of this treatment interval, conditioned media were assayed for PLA2 activity by conversion of PCDP substrate to PA. The results represent the mean ± SE of three independent experiments. Data were normalized relative to untreated control values.

 
IL-1ß-induced PLA2 expression and activity by cultured whole ovarian dispersates: dependence on nitric oxide
To determine whether the ability of IL-1ß to induce ovarian sPLA2 and cPLA2 gene expression and medium PLA2 activity is contingent upon endogenously produced nitric oxide, whole ovarian dispersates were cultured for 48 h in the absence or presence of IL-1ß (50 ng/ml) with or without AG, an established inhibitor of inducible ovarian nitric oxide synthase (22). As shown (Fig. 8Go), treatment with AG resulted in a modest, but significant (P < 0.01), increase in IL-1ß-stimulated medium PLA2 activity. Moreover, treatment with AG alone had no effect, but modestly increased the IL-1ß-induced expression of cPLA2 (P < 0.05; Fig. 9Go) and sPLA2 (P = 0.068; Fig. 10Go). These observations suggest a slight negative effect of nitric oxide on the ability of IL-1ß to induce cPLA2 (and possibly sPLA2) gene expression.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 8. IL-1ß-induced medium PLA2 activity in medium conditioned by whole ovarian dispersates: nitric oxide dependence. Whole ovarian dispersates (1.5 x 106 cells/dish) were cultured for 48 h in the presence of IL-1ß (50 ng/ml) with or without AG (0.4 mM). At the conclusion of this treatment interval, conditioned media were assayed for PLA2 activity as described in Fig. 7Go. The results represent the mean ± SE of three independent experiments. Data were normalized relative to IL-1ß-treated cells.

 


View larger version (46K):
[in this window]
[in a new window]
  		Figure 9. IL-1ß-induced cPLA2 gene expression: nitric oxide dependence. Whole ovarian dispersates (1.5 x 106 cells/dish) were cultured for 48 h in the absence or presence of IL-1ß (50 ng/ml) with or without AG (0.4 mM). The resultant RNA samples were subjected to a RNase protection assay using 32P-labeled rat antisense riboprobes for cPLA2 and RPL19 as described. The left panel depicts the mean ± SE of three experiments. In each experiment, data were normalized to the peak value. In the representative autoradiograph (right panel), the protected fragments are indicated in boldface.

 
Characterization of total cellular PLA2activity: time, cell density, calcium, and pH dependence
To establish the optimal duration of the PLA2 assay, cell sonicates from untreated whole ovarian dispersates were assayed for total cellular (cytosolic and secretory) PLA2 activity. An AA-containing substrate (PCSA) was used because it is cleaved by both PLA2 isoenzymes. As shown (Fig. 11AGo), the assay was linear with time for up to 90 min (r = 0.97). No further increments in activity could be detected thereafter. Accordingly, subsequent assays were routinely terminated after 1 h. The assay was also linear for cell density (Fig. 11AGo, inset) in the range used for subsequent assays (50–200 x 103 cells). To determine the optimal calcium concentration for the PLA2 assay, cell sonicates were assayed at the indicated Ca2+ concentration. As shown (Fig. 11BGo), total PLA2 activity was Ca2+ dependent, increasing from 0.2–20 mM Ca2+.



View larger version (36K):
[in this window]
[in a new window]
  		Figure 11. Characterization of ovarian cellular PLA2 activity. Whole ovarian dispersates (5 x 105 viable cell/tube) were cultured for 48 h in the absence of any treatment. At the conclusion of the incubation period, total cellular (cytosolic and secretory) PLA2 activity was determined by conversion of PCSA to AA. A, Time dependence experiments. PCSA, 5 µM; CaCl2, 2 mM (pH 8.0). Data reflecting the mean ± SE of the indicated number of experiments were normalized relative to the 60 min point. Similar conditions were used for a cell density dependence experiment (inset). B, Ca2+ concentration dependence experiments. PCSA, 5 µM; pH 8; duration of incubation, 1 h. Data reflecting the mean ± SE of the indicated number of experiments were normalized relative to a CaCl2 concentration of 2 mM. C, pH dependence experiments. PCSA, 5 µM; CaCl2, 2 mM; duration of incubation, 1 h. pH titration was accomplished using HEPES buffer over the range of 6.5–9.0. Data reflecting the mean ± SE of the indicated number of experiments (mean ± difference for n = 2) were normalized relative to pH 8.0.

 
As cPLA2 activity is calcium independent, and sPLA2 activity requires mM concentrations of Ca2+ (3), the doubling of PLA2 activity in the presence of 20 mM Ca2+ (Fig. 11BGo) suggests that whole ovarian dispersates contain equivalent quantities of each isoform. To determine the optimal pH for the PLA2 assay, cell sonicates were assayed at the indicated pH (Fig. 11CGo). PLA2 activity proved to be pH dependent, increasing from pH 6.5 to pH 8.0 with no further significant increments thereafter. These findings suggest an optimal pH of 8.0–9.0 for total cellular (cytosolic and secretory) PLA2 activity in the ovary, which is similar to reports for extraovarian sites (3).

Ovarian cellular PLA2 activity: kinetic parameters
To study the kinetics of ovarian PLA2, cell sonicates were assayed for total PLA2 activity in the presence of increasing concentrations of PCSA substrate. As shown (Fig. 12Go), provision of increasing concentrations of substrate (0.2–5 µM) resulted in a progressive increase in the product generated ([3H]AA). The velocity of the reaction approached saturation at 5 µM substrate. Km values for control (two separate experiments) and IL-1ß-treated (three separate experiments) cells were calculated using double reciprocal plots (a representative is shown in Fig. 12Go, inset). Values were variable, but in the same range for both groups: Km = 2.13 and 1.7 µM and 1.06, 4.0, and 5.9 µM for control and IL-1ß, respectively. These values must be viewed as crude estimates of the actual values, because the PLA2 reaction does not necessarily comply with the constraints imposed by the Michaelis-Menten equation. In fact, a substantial body of evidence supports the view that the kinetics of the PLA2 reaction are complex because of the need to establish optimal lipid-water interfacing (2). However, these data suggest that the kinetics of ovarian PLA2 activity are similar (both quantitatively and qualitatively) to the kinetics of PLA2 activity in other tissues (2).



View larger version (18K):
[in this window]
[in a new window]
  		Figure 12. Ovarian cellular PLA2 activity: kinetic parameters. Sonicates corresponding to 1.5 x 105 cells from either untreated or IL-1ß-treated whole ovarian dispersates (a representative IL-1ß-treated dispersate is shown) were assayed for PLA2 activity (1-h incubation) by conversion of PCSA to AA. Increasing concentrations (0.2–5 µM) of substrate (S) were added in duplicate. The inset depicts a corresponding double reciprocal (Lineweaver-Burk) plot. V, Reaction velocity.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The role of increased PLA2 activity as an inflammatory mediator is well established (23). Increased PLA2 activity was noted in a host of pathological processes (e.g. septic shock, connective tissue inflammatory diseases, premature labor, hypertension, and pancreatitis). However, this family of enzymes also plays many physiological roles, including (but not limited to) the facilitation of fat digestion, lung surfactant metabolism, cell membrane homeostasis, insulin release, sperm maturation, and lipoprotein metabolism (2, 3). This communication concerns itself with the potential relevance of PLA2 to ovarian physiology.

Our current observations document a nearly constant periovulatory level of sPLA2 transcripts and a negligible cPLA2 signal. It is possible that the modest fluctuation in the steady state levels of ovarian PLA2 transcripts reflects a dilutional effect by non-PLA2-expressing components of the ovary. Consequently, no meaningful information can be deduced as to PLA2 economy in individual ovarian follicles. Perhaps PLA2 is selectively expressed in rapidly growing follicles that are destined to ovulate. Such a hypothesis could be tested in an in vitro paradigm capable of sustaining follicular growth and maturation. Alternatively, the relevant PLA2 transcript is one other than the varieties probed for. Indeed, the growing family of PLA2s may feature other representatives in the ovary that have yet to be evaluated. This possibility is strongly supported by the realization that ovarian PLA2 activity is increased under in vivo circumstances in response to the LH surge, as reported by Bonney and Wilson (24).

Compelling evidence points to PG endoperoxide synthase (PGS-2) as the enzyme that is intimately associated with ovulation. Indeed, pharmacological (25, 26, 27, 28, 29, 30) or genetic (31) ablation of PGS-2 has been shown to arrest follicular rupture. Specifically, Hedin et al. (32) have unequivocally shown that the hCG-induced synthesis of PGs before ovulation is associated with a transient induction of PGS-2. In contrast, sPLA2 expression did not increase during the periovulatory period. Possibly, then, sPLA2 (unlike PGS-2) is constantly expressed in the ovary, setting the stage for the rate-limiting PGS-2 action detected during a narrow periovulatory window (32). Alternatively, other species of PLA2 may be at play, in that PLA2 is clearly up-regulated at midcycle in response to the LH surge, as documented by Bonney and Wilson (24).

One of the central observations made in this communication concerns the apparent IL-1ß dependence of PLA2 expression and activity. As both PGs (7) and IL-1ß (11, 12, 13, 14) may be involved in the ovulatory process, our present observations support the proposition that PLA2 may play a role in the context of follicular rupture. Moreover, PLA2 may be a component in the ability of IL-1ß to stimulate the biosynthesis of ovarian PGs (8). Although our findings constitute the first such report for the ovary, the ability of IL-1ß to induce PLA2 activity and to stimulate PG biosynthesis has been amply documented at multiple extraovarian sites (33, 34, 35, 36, 37, 38, 39, 40, 41).

IL-1ß-induced gene expression for both PLA2 subtypes requires de novo protein biosynthesis, as treatment with cycloheximide significantly decreased basal sPLA2 expression and medium PLA2 activity as well as the ability of IL-1ß to induce cPLA2 and sPLA2 transcripts. We speculate that the IL-1ß action requires the induction of its receptor (type I) before other end points can be affected. However, other intermediary proteins could be involved as well.

The relevance of nitric oxide to ovarian physiology was suggested by in vivo experiments demonstrating the ability of aminoguanidine (an inhibitor of inducible nitric oxide synthase) to suppress hCG-triggered ovulation in the rat (42). IL-1ß has been shown to markedly increase ovarian nitric oxide synthase activity (22, 43). In light of the above, we examined the impact of a nitric oxide vacuum (created by aminoguanidine) on the IL-1ß-induced expression of cPLA2 and sPLA2. Our results suggest that nitric oxide production may modestly down-regulate the PLA2 system. As the ovarian IL-1 system is characterized by its self-amplification property (44), nitric oxide may be an intraovarian regulator that can limit IL-1ß activity by decreasing PLA2 activity. Conceivably, without such a restraint, IL-1ß activity may lead to premature triggering of the ovulatory cascade.

Although the precise intraovarian role of PLA2 remains an evolving subject, there is little doubt that several representatives of the PLA2 family are expressed within the mammalian ovary and are subject to regulation. Both cPLA2 and sPLA2 transcripts are present in granulosa cells from untreated and periovulatory immature ovaries. It seems likely that sPLA2 is constitutively expressed (given its stronger in vitro and in situ signals), whereas cPLA2 may be considered inducible (given the relatively weak signal that is markedly stimulated by IL-1ß). Activity for both isoforms is present in cell sonicates based on calcium dependence studies. Moreover, pancreatic PLA2 (sPLA2 group I) has recently been introduced as a new player in ovarian physiology (45). A modest increase in ovarian PLA2 activity in response to the LH surge has also been reported (24). Although not evaluated in this report, PLA2 activity is reportedly subject to significant fluctuations during luteal regression in pseudopregnant and pregnant rats (46). Our present observations provide additional support for the growing significance of PLA2 in ovarian physiology.


   Acknowledgments
 
The authors thank Ms. Cornelia T. Szmajda for her invaluable assistance in the preparation of this manuscript.


   Footnotes
 
1 This work was supported in part by Research Grants HD-19998 and HD-30288 from the NICHHD, NIH (to E.Y.A.). Back

2 Recipient of a 1994 Merck Senior Fellow Award from the Endocrine Society and an American Physician Fellowship Award. Current address: Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel. Back

3 Recipient of a Fogarty International Fellowship Award, a Lalor Foundation Award, a Finnish Culture Foundation Award, and an Academy of Finland Award. Back

4 Recipient of a Lalor Foundation Fellowship, an International Fellowship Award from the Israeli Medical Association, a Fullbright Fellowship, and a Harlea Charitable Trust Award. Current address: Department of Obstetrics and Gynecology, Haemek Medical Center, Afula, Israel. Back

Received July 11, 1996.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Pruzanski W, Vadas P 1991 Phospholipase A2-mediator between proximal and distal effectors of inflammation. Immunol Today 12:143–146[Medline]
  2. Glaser KB, Mobilio D, Chang JY, Senko N 1993 Phospholipase A2 enzymes: regulation and inhibition. Trends Pharmacol Sci 14:92–98[CrossRef][Medline]
  3. Mayer RJ, Marshall L A 1993 New insights on mammalian phospholipase A2(s): comparison of arachidonyl-selective and nonselective enzymes. FASEB J 7:339–348[Abstract]
  4. Mukherjee AB, Miele L, Pattabiraman N 1994 Phospholipase A2 enzymes: regulation and physiological role. Biochem Pharmacol 48:1–10[CrossRef][Medline]
  5. Lambeau G, Ancian P, Barhanin J, Lazdunski M 1994 Cloning and expression of a membrane receptor for secretory phospholipase A2. J Biol Chem 269:1575–1578[Abstract/Free Full Text]
  6. Ishizaki J, Hanasaki K, Higashino K, Kishino J, Kikuchi N, Ohara O, Arita H 1994 Molecular cloning of pancreatic group I phospholipase A2 receptor. J Biol Chem 269:5897–5904[Abstract/Free Full Text]
  7. Poyser NL 1987 Prostaglandin and ovarian function. In: Hillier K (ed) Advances in Eicosanoid Research. MTP Press, London, pp 1–29
  8. Kokia E, Hurwitz A, Ricciarelli E, Tedeschi C, Resnick CE, Mitchell MD, Adashi EY 1992 Interleukin-1 stimulates ovarian prostaglandin biosynthesis: evidence for heterologous contact-independent cell-cell interaction. Endocrinology 130:3095–3097[Abstract/Free Full Text]
  9. Brännström M, Wang L, Norman RG 1993 Effects of cytokines on prostaglandin production and steroidogenesis of incubated preovulatory follicles of the rat. Biol Reprod 48:165–171[Abstract]
  10. Towson DH, Pate JL 1994 Regulation of prostaglandin synthesis by interleukin-1 in cultured bovine luteal cells. Biol Reprod 51:480–485[Abstract]
  11. Brannstrom M, Wang L, Norman R 1993 Ovulatory effect of interleukin-1ß on the perfused rat ovary. Endocrinology 132:399–404[Abstract/Free Full Text]
  12. Peterson C, Hales H, Hatasaka H, Mitchell M, Rittenhouse L, Jones K 1993 Interleukin-1ß (IL-1ß) modulates prostaglandin production and the natural IL-1 receptor antagonist inhibits ovulation in the optimally stimulated rat ovarian perfusion model. Endocrinology 133:2301–2306[Abstract/Free Full Text]
  13. Takehara Y, Dharmarajan A, Kaufman G, Wallach E 1994 Effect of interleukin-1ß on ovulation in the in vitro perfused rabbit ovary. Endocrinology 134:1788–1793[Abstract/Free Full Text]
  14. Simón C, Tsafriri A, Chun S-Y, Piquette GN, Dang W, Polan ML 1994 Interleukin-1 receptor antagonist suppresses hCG-induced ovulation in the rat. Biol Reprod 51:662–667[Abstract]
  15. Ben-Shlomo I, Hurwitz A, Kokia E, Scherzer WJ, Rohan RM, Payne DW, Adashi EY 1994 Role of cytokines in ovarian physiology: interleukin-1 as a possible centerpiece in the ovulatory sequence. In: Aggarwal B, Puri P (eds) Human Cytokine: Their Role in Disease and Therapy. Blackwell, Cambridge, pp 329–333
  16. Hurwitz A, Payne DW, Packman JN, Andreani CL, Resnick CE, Hernandez ER, Adashi EY 1991 Cytokine mediated regulation of ovarian function: interleukin-1 inhibits gonadotropin induced androgen biosynthesis. Endocrinology 129:1250–1256[Abstract/Free Full Text]
  17. Ishizaki J, Ohara O, Nakamura E, Tamaki M, Ono T, Kanda A, Yoshida N, Teraoka H, Tojo H, Okamoto M 1989 cDNA cloning and sequence determination of rat membrane-associated phospholipase A2. Biochem Biophys Res Commun 162:1030–1036[CrossRef][Medline]
  18. Owada Y, Tominaga T, Yoshimoto T, Kondo H 1994 Molecular cloning of rat cDNA for cytosolic phospholipase A2 and the increased gene expression in the dentate gyrus following transient forebrain ischemia. Mol Brain Res 25:364–368[Medline]
  19. Scherzer WJ, Ruutiainen-Altman KSL, Putowski LT, Kol S, Adashi EY, Rohan RM 1996 Detection and in vivo hormonal regulation of rat ovarian type I and type II interleukin-1 receptor mRNAs: increased expression during the periovulatory period. J Soc Gynecol Invest 3:131–140[CrossRef][Medline]
  20. Kol S, Ben-Shlomo I, Adashi EY, Rohan RM 1996 Simplified riboprobe purification using translucent straws as gel tubes. Genet Anal Biomol Engin 12:129–132
  21. Lowe Jr WL, Roberts Jr CT, Lasky SR, LeRoith D 1987 Differential expression of alternative 5' untranslalated regions in mRNA encoding rat insulin-like growth factor 1. Proc Natl Acad Sci USA 84:8946–8950[Abstract/Free Full Text]
  22. Ben-Shlomo I, Kokia E, Jackson M, Adashi EY, Payne DW 1994 Interleukin-1ß stimulates nitrate production in the rat ovary: evidence for heterologous cell-cell interaction and for insulin-mediated regulation of the inducible isoform of nitric oxide synthase. Biol Reprod 51:310–318[Abstract]
  23. Mukherjee AB 1990 PLA2 central role in inflammation. In: Mukherjee AB (ed) Biochemistry, Molecular Biology and Physiology of Phospholipase A2 and its Regulatory Factors. Plenum Press, New York and London, pp 52–60
  24. Bonney RC, Wilson CA 1993 Hormonal control of ovarian phospholipase A2 activity in rats. J Reprod Fertil 99:201–208[Abstract/Free Full Text]
  25. Tsafriri A, Koch Y, Lindner HR 1973 Ovulation rate and serum LH levels in rats treated with indomethacin or prostaglandin E2. Prostaglandins 3:461–467[CrossRef][Medline]
  26. Hamada Y, Bronson RA, Wright KH, Wallach EE 1977 Ovulation in the perfused rabbit ovary: the influences of prostaglandins and prostaglandin inhibitors. Biol Reprod 17:58–63[Abstract]
  27. Downey BR, Ainsworth L 1980 Reversal of indomethacin blockade of ovulation in gilts by prostaglandins. Prostaglandins 19:17–22[CrossRef][Medline]
  28. Espey LL, Norris C, Saphire D 1986 Effect of time and dose of indomethacin on follicular prostaglandins and ovulation in the rabbit. Endocrinology 119:746–754[Abstract/Free Full Text]
  29. Schmidt G, Holmes PV, Owman CH, Sjoberg NO, Walles B 1986 The influence of prostaglandin E2 and indomethacin on progesterone production and ovulation in the rabbit ovary perfused in vitro. Biol Reprod 35:815–821[Abstract]
  30. Sogn JH, Curry TE Jr, Brannstrom M, LeMaire WJ, Koos RD, Papkoff H, Janson PO 1987 Inhibition of follicle-stimulating hormone-induced ovulation by indomethacin in the perfused rat ovary. Biol Reprod 36:536–542[Abstract]
  31. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM 1995 Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 372:406–409
  32. Hedin L, Gaddy-Kurten D, Kurten R, DeWitt DL, Smith WL, Richards JS 1987 Prostaglandin endoperoxide synthase in rat ovarian follicles: content, cellular distribution, and evidence for hormonal induction preceding ovulation. Endocrinology 121:722–731[Abstract/Free Full Text]
  33. Burch RM, Connor JR, Axelrod J 1988 Interleukin 1 amplifies receptor-mediated activation of phospholipase A2 in 3T3 fibroblasts. Proc Natl Acad Sci USA 85:6306–6309[Abstract/Free Full Text]
  34. Nakazato Y, Simonson MS, Herman WH Konieczkowski M, Sedor JR 1991 Interleukin-1{alpha} stimulates prostaglandin biosynthesis in serum-activated mesangial cells by induction of a non-pancreatic (type II) phospholipase A2. J Biol Chem 266:14119–14127[Abstract/Free Full Text]
  35. Cisar LA, Schimmel RJ, Mochan E 1991 Interleukin-1 stimulation of arachidonic acid release from human synovial fibroblasts; blockade by inhibitors of protein kinases and protein synthesis. Cell Signal 3:189–199[CrossRef][Medline]
  36. Schalkwijk C, Pfeilschifter J, Marki F, van den Bosch H 1991 Interleukin-1ß, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells. Biochem Biophys Res Commun 174:268–275[CrossRef][Medline]
  37. Pfeilschifter J, Leighton J, Pignat W, Marki F, Vosbeck K 1991 Cyclic AMP mimics, but not mediate, interleukin-1- and tumor-necrosis factor-stimulated phospholipase A2 secretion from rat renal mesangial cells. Biochem J 273:199–204
  38. Schalkwijk C, Pfeilschifter J, Marki F, van den Bosch H 1991 Interleukin-1ß and forskolin-induced synthesis and secretion of group II phospholipase A2 and prostaglandin E2 in rat mesangial cells is prevented by transforming growth factor-ß2. J Biol Chem 1992;267:8846–8851
  39. Bomalaski JS, Steiner MR, Simon PL, Clark MA 1992 IL-1 increases phospholipase A2 activity expression of phospholipase A2 activating protein and release of linoleic acid from the murine T helper cell line EL-4. J Immunol 148:155–160[Abstract]
  40. Shinohara H, Amabe Y, Komatsubara T, Tojo H, Okamoto M, Wakano Y, Ishida H 1992 Group II phospholipase A2 induced by interleukin-1ß in cultured rat gingival fibroblasts. FEBS Lett 304:69–72[CrossRef][Medline]
  41. Hulkower KI, Hope WC, Chen T, Anderson CM, Coffey JW, Morgan DW 1992 Interleukin-1ß stimulates cytosolic phospholipase A2 in rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 184:712–718[CrossRef][Medline]
  42. Shukovski L, Tsafriri A 1994 The involvement of nitric oxide in the ovulatory process in the rat. Endocrinology 135:2287–2290[Abstract]
  43. Ellman C, Corbett JA, Misko T, McDaniel M, Beckerman KP 1993 Nitric oxide mediates interleukin-1-induced cellular cytotoxicity in the rat ovary: a potential role for nitric oxide in the ovulatory process. J Clin Invest 92:3053–3056
  44. Hurwitz A, Ricciarelli E, Botero L, Rohan RM, Hernandez ER, Adashi E Y 1991 Endocrine- and autocrine-mediated regulation of rat ovarian (theca-interstitial) interleukin-1ß gene expression: gonadotropin-dependent preovulatory acquisition. Endocrinology 129:3427–3429[Abstract/Free Full Text]
  45. Nomura K, Fujita H, Arita H 1994 Gene expression of pancreatic-type phospholipase-A2 in rat ovaries: stimulatory action on progesterone release. Endocrinology 135:603–609[Abstract]
  46. Wu XM, Carlson JC 1990 Alterations in phospholipase A2 activity during luteal regression in pseudopregnant and pregnant rats. Endocrinology 127:2464–2468[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Biol. Reprod.Home page
M. N. Diouf, K. Sayasith, R. Lefebvre, D. W. Silversides, J. Sirois, and J. G. Lussier
Expression of Phospholipase A2 Group IVA (PLA2G4A) Is Upregulated by Human Chorionic Gonadotropin in Bovine Granulosa Cells of Ovulatory Follicles
Biol Reprod, June 1, 2006; 74(6): 1096 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Landreville, S. Coulombe, P. Carrier, M. H. Gelb, S. L. Guerin, and C. Salesse
Expression of Phospholipases A2 and C in Human Corneal Epithelial Cells
Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 3997 - 4003.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Chamson-Reig, E. M. Sorianello, P. N. Catalano, M. O. Fernandez, O. P. Pignataro, C. Libertun, and V. A. R. Lux-Lantos
Gonadotropin-Releasing Hormone Signaling Pathways in an Experimental Ovarian Tumor
Endocrinology, July 1, 2003; 144(7): 2957 - 2966.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
J. Saito, M. Ando, D. Sussman, H. Negishi, G. King, and E. Y. Adashi
Interleukin 1 Upregulates Ovarian Prostaglandin Endoperoxide Synthase-2 Expression: Evidence for Prostaglandin-Dependent/Ceramide-Independent Transcriptional Stimulation and for Message Stabilization
Biol Reprod, December 1, 2001; 65(6): 1759 - 1765.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Chamson-Reig, O. P. Pignataro, C. Libertun, and V. A. R. Lux-Lantos
Alterations in Intracellular Messengers Mobilized by Gonadotropin-Releasing Hormone in an Experimental Ovarian Tumor
Endocrinology, August 1, 1999; 140(8): 3573 - 3580.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Saunders, M. G. Belvisi, G. Cirino, P. J. Barnes, T. D. Warner, and J. A. Mitchell
Mechanisms of Prostaglandin E2 Release by Intact Cells Expressing Cyclooxygenase-2: Evidence for a `Two-Component' Model
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1101 - 1106.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kol, S.
Right arrow Articles by Adashi, E. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kol, S.
Right arrow Articles by Adashi, E. Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
*NITRIC OXIDE

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals